Cortikan

Quick links to important sections

Cortikan

Method of action: Antihemorrhoidal

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Cortikan

Quick Facts

Property Description
Active Ingredients Hydrocortisone, Neomycin
Form Topical Preparation (Cream, Ointment, Otic Suspension)
Pharmacological Class Anti-inflammatory and Anti-infective Combination
Common Type Fixed-Dose Combination (FDC) Product
Origin Semi-synthetic (Corticosteroid) and Synthetic (Antibiotic)

Defining Cortikan: A Fixed-Dose Combination Drug

Cortikan is defined as a Fixed-dose combination (FDC) product, which is a prescription-only medicine belonging to the specialized Anti-inflammatory and Anti-infective Combination class. This structural design dictates that the two primary active ingredients are formulated together in a single topical preparation, such as an ointment, cream, or specialized otic suspension. Unlike therapies that rely on a single agent, this FDC is specifically positioned to treat conditions where both inflammation and bacterial infection are simultaneously present. Hydrocortisone, the corticosteroid component, is used topically for its clinically recognized anti-inflammatory and antipruritic properties.

Composition and Pharmacological Class of Cortikan

The efficacy of Cortikan stems from its two active ingredients: the glucocorticoid Hydrocortisone and the aminoglycoside antibiotic Neomycin. Hydrocortisone is a semi-synthetic corticosteroid that manages the local immune response. Neomycin is a synthetic compound that provides the necessary anti-infective action by exhibiting bactericidal activity. This pairing of topical corticosteroids with aminoglycosides is well-established for treating inflammatory skin conditions where a bacterial component is present or anticipated.

General Purpose: The Dual Action Benefit

The general purpose of Cortikan is to deliver powerful, localized relief by utilizing this comprehensive dual-mechanism of action. The synergistic action ensures that the Hydrocortisone component rapidly eases symptoms like redness and itching, while the Neomycin component works to control and neutralize bacterial growth. This combined approach provides a targeted treatment for irritated areas, addressing both the underlying inflammation and the co-existing infective element in a single step.

Regulatory References

  1. Hydrocortisone Ointment Monograph
  2. Hydrocortisone/Neomycin Cream Monograph
  3. Bacterial Infections (MedlinePlus)
  4. NIH Clinical Research Basics
  5. Hydrocortisone Topical Monograph
  6. Glucocorticoids Overview (NIH)
  7. Neomycin Topical Monograph
  8. Anti-infective Agents (MeSH/NIH)
  9. Bactericidal Agents (MeSH/NIH)
  10. Drug Synergism (MeSH/NIH)
  11. MedlinePlus - NIH Drug Information
  12. Corticosteroid-Antibiotic Combination Monograph

What side effects are possible with Cortikan ?

Possible Side Effects and Safety Information

The safety profile for this fixed-dose combination product is characterized by the potential adverse reactions associated with its two active components, hydrocortisone and neomycin. The official regulatory classification of side effects often reports many topical reactions as Frequency Not Known due to insufficient data for reliable estimation, though local effects such as burning, itching, and irritation at the application site are frequently listed in regulatory documents.

Serious safety concerns are primarily linked to the possibility of the active ingredients being absorbed systemically. The neomycin component is associated with potential ototoxicity (damage to the ear, potentially leading to hearing loss) and nephrotoxicity (effects on the kidneys). The hydrocortisone component carries the risk of reversible hypothalamic-pituitary-adrenal (HPA) axis suppression and manifestations of Cushing’s syndrome following significant systemic absorption.

This systemic risk is officially documented as being elevated when the medication is used on large surface areas, under occlusive dressings, or on broken or damaged skin. Safety statements further specify that prolonged or long-term continuous use increases the likelihood of systemic effects and local adverse reactions, such as skin atrophy or striae.

Population-specific safety considerations documented in official labeling note that pediatric patients may be more susceptible to HPA axis suppression. Additionally, the risk of neomycin-induced ototoxicity is significantly heightened in patients with a perforated tympanic membrane.

Overdose and Emergency Response

Overdose and when to seek help

Overdose is primarily linked to the systemic absorption of the active ingredients, a risk that increases with prolonged use, application over extensive body areas, or use under occlusive dressings. Excessive systemic exposure to the hydrocortisone component may lead to signs of exogenous hyperadrenocorticism and adrenal suppression.

Overexposure to the neomycin component carries risks of serious organ toxicity. Documented manifestations include ototoxicity, which can result in permanent sensorineural hearing loss, and nephrotoxicity (kidney damage). Severe, life-threatening outcomes such as neuromuscular blockade and respiratory paralysis have been formally described in cases of high systemic neomycin levels.

Special consideration must be given to pediatric patients due to an increased risk of systemic effects, including HPA axis suppression and the potential for growth cessation. Patients with pre-existing impaired renal function are also at a heightened risk for neomycin-related toxicities.

The official regulatory guidance mandates that suspected overdose must be managed with symptomatic and supportive treatment. Immediate medical attention is required if the affected individual has collapsed, is experiencing trouble breathing, has had a seizure, or cannot be awakened. While no specific antidote is known, procedures such as hemodialysis may be required for managing severe neomycin toxicity.

Therapeutic Uses of Cortikan

What Cortikan Treats: Main Uses and Benefits

Cortikan is commonly used in therapeutic domains where symptoms related to inflammatory or irritative states and a risk of bacterial infection are present, providing supportive symptomatic management.

The combination of hydrocortisone and neomycin is used for managing symptoms associated with superficial bacterial infections of the external auditory canal. This combination generally helps ease the overall symptom load associated with both infective and inflammatory manifestations.

The medication is relevant for conditions such as corticosteroid-responsive dermatoses complicated by secondary bacterial infection and acute external ear infections, specifically Otitis Externa.

Key Symptom Management

This medication is applied in clinical settings for conditions characterized by symptoms that interfere with daily functioning, including redness, swelling, and itching alongside the presence of bacteria. The use contributes to improved comfort during periods of heightened symptoms by providing supportive relief when symptoms intensify.

Quick Fact: Relief for Dual Discomfort

Property Description
Symptom Cluster Inflammation (swelling/redness) and Bacterial Presence
Benefit Focus Supports general well-being during symptomatic phases
Clinical Scenario Acute episodes of secondary skin infection or ear infection
Resulting Comfort Helps maintain a sense of stability when symptoms are more noticeable

Eligibility and Restrictions for Use

Who Can and Cannot Use Cortikan?

Cortikan use is governed by strict regulatory eligibility criteria, with absolute prohibitions and population-specific limitations defined in official labeling. The medicine is allowed for adults and adolescents only if no contraindications are present.

Contraindicated Populations (Must Not Use)

The medicine is contraindicated for:

  • Individuals with a known hypersensitivity to Hydrocortisone, Neomycin, or any other component.
  • Patients with cutaneous viral infections (such as Herpes Simplex or Varicella Zoster) or tuberculous/fungal lesions in the treatment area.
  • The otic formulation is absolutely forbidden if the patient has a perforated tympanic membrane (ruptured eardrum).

Restricted Populations and Age Rules

Safety and effectiveness have not been established in pediatric patients. Prolonged use in children is subject to regulatory warnings due to the risk of systemic absorption.

Treatment is generally restricted to 7 to 10 consecutive days to mitigate the potential for Neomycin-associated ototoxicity.

The medicine is classified as Pregnancy Category C, meaning it should be used only if the potential benefit clearly justifies the potential risk to the fetus; caution is also required during lactation.

What should I know about interactions with other medicines?

Cortikan Interactions with other medicines and products

This section outlines the officially documented interaction profile for the Hydrocortisone and Neomycin combination product, based strictly on government regulatory labeling.


Documented Interaction Patterns and Restrictions

Property Classification & Context
Allergic Cross-Sensitization The use of Cortikan is contraindicated if there is a known hypersensitivity to the product's components or to cross-sensitizing aminoglycoside antibiotics such as Kanamycin, Framycetin, Gentamicin, or Streptomycin.
Pharmacodynamic Potentiation The Neomycin component carries a caution regarding co-administration with neuromuscular blocking agents. Significant systemic absorption may intensify and prolong the respiratory depressant effect of these agents, as noted in official regulatory documents.

Population-Specific Interaction Notes

Interaction-related cautions are specified for certain patient populations where the risk of systemic exposure or reduced clearance is relevant:

  • Reduced Clearance in Renal Impairment: Caution is necessary in patients with reduced renal function because the plasma clearance of Neomycin is lowered, increasing the potential for systemic exposure.
  • Increased Absorption Potential in Children: Official labeling notes an increased potential for systemic absorption of the components in very young children (infants up to 2 years), which necessitates specific regulatory caution.

No interactions with food, alcohol, or herbal products are explicitly documented in the regulatory prescribing information for this topical combination.

Mechanism of Action

Cortikan is a synthetic glucocorticoid agonist that operates by binding with high affinity to the intracellular glucocorticoid receptor (GR) complex, distributed widely across immune, skin, and vascular cells. This interaction causes the ligand-receptor complex to translocate into the cell nucleus, initiating the primary molecular actions of the compound.

Within the nucleus, the Cortikan-GR complex modulates gene transcription through both genomic and non-genomic mechanisms. The genomic action involves the complex binding directly to glucocorticoid response elements (GREs) on the DNA, which upregulates the transcription of anti-inflammatory proteins, such as annexin-A1. Conversely, the complex also acts by interacting with and inhibiting the activity of pro-inflammatory transcription factors like NF-kappaB and AP-1. The resultant downstream cascades include a significant reduction in the synthesis and release of key pro-inflammatory cytokines, chemokines, and mediators. Physiologically, this leads to a decrease in the migration and activity of immune cells, a reduction in the release of vasoactive substances, and decreased vascular permeability. The system-level consequence is a broad, dampened modulation of localized inflammatory responses.

Dosage and Administration Information

Administration Overview

Cortikan is a topical corticosteroid designed for application to the skin. Proper usage involves applying the medication to the affected areas as determined by a healthcare professional. It is intended for external use only and should be handled with care to ensure the medication remains on the targeted treatment site.

Application Process

When using this medication, it is standard practice to clean and dry the affected area before application. A thin layer is typically spread over the skin and rubbed in gently until it is no longer visible.

Usage Considerations

  • Target Areas: The medication is applied specifically to the regions of the skin requiring treatment.
  • Hand Hygiene: Hands should be washed thoroughly before and after application, unless the hands themselves are the area being treated.
  • Occlusive Dressings: The treated area should remain uncovered unless otherwise specified by a healthcare provider, as covering the area with bandages or plastic wrap can alter the absorption rate of the medication.

Important Usage Notes

To maintain the integrity of the treatment, avoid contact with the eyes, nose, or mouth. If the medication comes into contact with these areas, they should be rinsed thoroughly with water. Additionally, consistency in application helps maintain the intended effect on the skin's surface.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Cortikan

This section provides an overview of the types of research that have been conducted to evaluate the combination of Hydrocortisone and Neomycin, focusing on what studies explored and what the current evidence base suggests, according to official and peer-reviewed sources. It does not offer clinical guidance or personal predictions.


Evidence for Use in Acute External Ear Infection

Research evaluated the use of this combination in the external ear canal primarily through short-term Randomized Controlled Trials (RCTs) and systematic reviews. Research examined outcomes related to physical discomfort and acute changes, such as the time until the end of pain and whether studies recorded clinical patterns (defined by observed changes in symptoms like swelling and ear discharge). Studies also explored whether research monitored microbiological clearance, meaning the reduction of susceptible bacteria from the ear canal.

Studies conducted during periods of increased symptom activity documented measurements in the combination group and in the comparator groups (including non-active preparations). Findings describe patterns observed in the studies related to how patients reported their experience over defined time intervals. Comparative data specifically for the dual Hydrocortisone/Neomycin product alone is limited, as some evidence relied upon is derived from studies of a triple-combination product.


Evidence for Use in Corticosteroid-Responsive Dermatoses

The research foundation for the topical cream or ointment, applied to inflammatory skin conditions complicated by secondary bacterial infection, includes clinical trials and comparative studies cited in regulatory documents. Studies explored outcomes linked to inflammatory or irritative states, such as measuring changes in specific signs like redness, itching, and swelling, as well as the clearance of the secondary infection, using outcomes related to overall measured change and patient-reported discomfort.

Regulatory frames note that evidence regarding the role of the combination beyond the corticosteroid component alone is limited when treatment is extended past 7 consecutive days. The initial research exploring short-term symptom changes monitored outcomes only up to this defined time interval. Consequently, data exploring use beyond this short period are insufficient.


What is Still Uncertain About the Evidence Base

The evidence landscape, while providing context for short-term symptom patterns, still contains important research gaps. A primary limitation is that comparative evidence is lacking to fully differentiate the specific short-term role of the dual Hydrocortisone/Neomycin product from similar combinations. Long-term data are not available, and research does not provide insight into the patterns of observed changes over time or whether the use of the combination is associated with the future frequency of symptom flare-ups. Furthermore, findings describe group patterns, not personal outcomes, and data for certain subgroups remain uncertain.

Key Studies & References CORTISPORIN - neomycin sulfate, polymyxin b sulfate and hydrocortisone acetate cream, Product Information (DailyMed)

Frequently Asked Questions (FAQ)

Common questions about Cortikan (FAQ)

Q: Can Cortikan affect my sleep?

A: Specific sleep changes are not commonly listed for this topical or otic product. The hydrocortisone component is a corticosteroid, and official information notes that systemic absorption, which is possible with prolonged or extensive use, can lead to central nervous system effects, which may include altered sleep patterns, though this is not commonly reported for the local product.


Q: Is it normal to feel a bit nauseous when starting Cortikan?

A: Nausea or other stomach issues are not listed as the most common local side effects for Cortikan. Nonetheless, regulatory data indicates that rare instances of gastrointestinal disturbances, such as nausea or vomiting, have been reported with the use of this combination product.


Q: Can I take Cortikan if I have high blood pressure?

A: Regulatory warnings state that caution is necessary for patients with certain pre-existing conditions. If the hydrocortisone component is significantly absorbed into the bloodstream, it can cause the body to retain salt and fluid. This effect could potentially contribute to an elevation of blood pressure.


Q: How long can someone safely stay on Cortikan?

A: Regulatory documents state that treatment with Cortikan should be limited to a maximum of 7 to 10 consecutive days. Using the medication for longer periods increases the risk of systemic effects, such as the suppression of the HPA axis (adrenal function), and increases the likelihood of local side effects like skin thinning.


Q: Can Cortikan cause weight gain?

A: Weight gain is not explicitly listed as a side effect for the topical/otic product. However, the hydrocortisone component is a corticosteroid, a class of medicine known to cause metabolic changes, including weight gain, if significant amounts are absorbed systemically.


Q: Is Cortikan safe for older adults?

A: Official reports indicate that clinical studies did not include enough older adults (aged 65 and over) to fully determine if their response differs from younger patients. However, general post-market experience has not identified differences in how the elderly react to the medicine compared to younger adults.


Q: Are there any long-term side effects associated with Cortikan use?

A: This product is strictly intended for short-term use. The official warnings state that prolonged continuous use may increase the likelihood of developing systemic effects, and the labeling advises seeking further evaluation if the condition does not improve after 1 week.


Q: Why do some people experience mood changes on Cortikan?

A: Mood changes are not a common local side effect. Systemic absorption of the hydrocortisone component, especially with long-term or widespread use, may lead to psychological disturbances and mood changes, which are known risks associated with systemic corticosteroid use.


Q: Are there any dietary restrictions I need to follow with Cortikan?

A: Official drug interaction documents do not list any explicit restrictions or known interactions with food, alcohol, or herbal products for this topical and otic combination medicine.


Q: Can Cortikan be crushed or split if it's hard to swallow?

A: Cortikan is formulated only as a cream, ointment, or otic (ear) suspension, not as an oral tablet or capsule. Therefore, it is not meant to be swallowed, crushed, or split.


Q: Can Cortikan cause thinning of the skin with long-term use?

A: Regulatory documents indicate that prolonged or continuous use of topical Cortikan is associated with a risk of local side effects. These reactions can include skin atrophy, which is the medical term for the irreversible thinning or weakening of the skin.


Q: Does Cortikan affect my blood sugar levels?

A: The hydrocortisone component of the product, when absorbed into the body, is known to potentially produce metabolic changes. These effects can include an elevation of blood glucose (sugar) levels, which is a potential risk, particularly when the drug is used on large areas of skin or for long periods.


Q: Are there any known withdrawal symptoms if I stop Cortikan suddenly?

A: Regulatory warnings indicate that abrupt discontinuation of Cortikan, particularly after extended use, may lead to signs of acute adrenal insufficiency. This is due to the risk of reversible HPA axis suppression (where the body temporarily stops producing its own natural steroids).


Q: Why do doctors often tell you to 'taper' off Cortikan?

A: Tapering, or gradually reducing the use of the medicine, is a precaution recommended after long-term therapy. This is done to minimize the risk of acute adrenal insufficiency, which can occur if the medication is stopped suddenly due to the temporary suppression of the HPA axis.


Q: Can Cortikan cause headaches?

A: Headaches are not listed among the frequently reported local side effects for the topical or otic product. However, a headache is a known neurological adverse reaction associated with the systemic use of corticosteroids, which is the class of drug in Cortikan.


Q: What are the signs of an allergic reaction to Cortikan?

A: Signs of a reaction to the neomycin antibiotic component may include local symptoms such as low-grade redness, swelling, dry scaling, or itching that appear worse than the original condition. Official guidance recommends immediately stopping the use of the product if signs of irritation or sensitivity occur.


Q: Are there different strengths of Cortikan available?

A: Official documents generally list the Cortikan combination product as being available in one standard strength formulation for its various forms, including the topical cream, ointment, and otic suspension.


Q: Can a person with kidney disease take Cortikan?

A: Regulatory documents note that caution is necessary for patients with reduced kidney function. The neomycin component is cleared from the body more slowly in these individuals, which increases the potential for systemic exposure and related risks.


Q: Does Cortikan affect your immune system?

A: The labeling indicates the hydrocortisone component is a glucocorticoid, which operates by suppressing the inflammatory response. Prolonged use may inhibit the body's natural defense mechanisms and could result in the overgrowth of other organisms, such as fungi.


Q: Is it okay to take Cortikan for a few days and then stop?

A: Cortikan is intended only for a short course of treatment, typically lasting 7 to 10 days. Official labeling advises seeking further evaluation if the condition does not improve after 1 week.


Q: Can pregnant women or those planning a pregnancy use Cortikan?

A: Cortikan is classified by the FDA as Pregnancy Category C. This classification means the medication should only be used during pregnancy if the potential benefit from the treatment is clearly judged to outweigh any potential risks to the developing fetus.


Q: Is Cortikan the same as hydrocortisone?

A: Cortikan is defined as a Fixed-Dose Combination product. It contains the anti-inflammatory drug Hydrocortisone and the antibiotic drug Neomycin formulated together; Hydrocortisone is only one of the two active ingredients.


Q: Is it normal for my stomach to feel upset a few hours after taking Cortikan?

A: While not a common local side effect, rare reports of gastrointestinal issues exist. If symptoms such as stomach upset or nausea occur, seeking guidance from a healthcare professional is advised.


Q: Are Cortikan side effects less common if taken with food?

A: This question is generally not applicable to Cortikan. Since it is approved only for topical (skin) and otic (ear) application, it is not meant to be taken orally with food.


Q: Can I drink coffee while taking Cortikan?

A: Official regulatory documents, which detail drug interactions, do not list any documented interactions between this topical combination product and caffeinated beverages like coffee.

How should Cortikan be stored and disposed of?

How to Store and Dispose of Cortikan

The storage and disposal of this medication must adhere strictly to official regulatory guidelines to maintain its stability and ensure safety.


Storage Requirements

The product must be stored at Controlled Room Temperature, typically 20 C to 25 C (68 F to 77 F). It is a mandatory requirement to keep Cortikan from freezing and to store it away from excessive heat and moisture. The container must be kept tightly closed when not in use. For liquid formulations, follow instructions such as shaking well before use and avoiding contamination of the bottle tip.

Constraint Requirement
Temperature Controlled Room Temperature
Prohibition Do not freeze; avoid excessive heat
Child Safety Keep out of the sight and reach of children

Disposal and Stability

For certain multi-dose products (e.g., ear drops), the container must be discarded within one month of first opening. The official guidance states to discard any unused portion after treatment. Unused or expired topical medicines should be disposed of by mixing the drug with an undesirable substance and sealing it in a container for placement in household trash, if a drug take-back program is unavailable.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Cortikan  found in:

A-Z Index: